Chris Chen, WuXi Biologics CEO (Photographer: Anthony Kwan/Bloomberg via Getty Images)
August 20, 2024 03:02 PM EDTUpdated 03:38 PM
China
Manufacturing

WuXi Bi­o­log­ics’ ADC spin­out re­ports rev­enue jump de­spite Biose­cure risk

Anna Brown

News Reporter

AD­Cs are so hot that WuXi Bi­o­log­ics’ spe­cial­ist com­pa­ny has so far ap­peared im­mune to the Biose­cure threat as it un­veiled a rise in rev­enues …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times